Exact Sciences' Q4 results beat analysts' expectations : vim

Exact Sciences has applied for federal approval of a “next-generation” Cologuard test, meaning the new version of its stool-based test to screen for colon cancer could become available by 2025.

Related Keywords

Kevin Conroy , Zacks Investment Research , Sciences Corp , Madison Based Exact Sciences , Exact Sciences , Cologuard , Earnings , Business , Ota ,